Soligenix Stock Nearly Doubles Before the Bell as Ebola Vaccine Hopes Put Tiny Biotech Back in Play
Soligenix Inc. shares nearly doubled in pre-market trading on Wednesday after the low-priced biotech tied its ThermoVax vaccine-stabilization technology to the Bundibugyo Ebola outbreak in Congo and Uganda, extending a sharp gain from Tuesday’s regular session. Google Finance showed SNGX at $1.00 pre-market, up 94.6% from a $0.51 close; a market-data feed listed the latest regular-market price at $0.513.
